- Home
- DNTH
as 09-05-2025 4:00pm EST
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 780.2M | IPO Year: | N/A |
| Target Price: | $54.00 | AVG Volume (30 days): | 374.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.37 - $32.27 | Next Earning Date: | 11-06-2025 |
| Revenue: | $4,854,000 | Revenue Growth: | 17.87% |
| Revenue Growth (this year): | -53.25% | Revenue Growth (next year): | -13.24% |
Latest Dianthus Therapeutics Inc. News
DNTH Breaking Stock News: Dive into DNTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewswire
3 months ago
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
GlobeNewswire
4 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewswire
4 months ago
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
GlobeNewswire
4 months ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
Simply Wall St.
6 months ago
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate
Simply Wall St.
6 months ago
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations
GlobeNewswire
6 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Compare DNTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNTH Dianthus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.